Medical device company Moximed reported five-year data showing sustained pain relief, functional improvement and durability for its Misha knee system in patients with medial knee osteoarthritis.
The findings, published in the Journal of Bone and Joint Surgery, followed 81 patients from the device’s pivotal investigational device exemption trial for five years after implantation, according to a June 23 news release. The original multicenter study enrolled 162 patients and previously found the Misha knee system outperformed high-tibial osteotomy at two years.
At five years, 96% of patients achieved clinically meaningful improvement in pain and 86% had clinically meaningful improvement in function. In addition, 90% had not required conversion to arthroplasty or high-tibial osteotomy.
The study included patients with early to severe medial knee osteoarthritis who had experienced symptoms for more than four years on average and had not responded to nonsurgical treatment.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
